Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• "Moderate Buy" consensus from 11 analysts (9 buy, 1 hold, 1 sell) with an average 12‑month target of $140.63 and recent price-target hikes (HC Wainwright raised its target to $185).
• Multiple securities class action filings and investor notices allege misstatements related to the REZOLVE‑AA trial and Feb–Dec 2025 disclosures, elevating litigation, discovery and potential settlement risk that could pressure valuation.
• Nektar beat quarterly estimates (EPS -$1.78 vs. -$2.69; revenue $21.8M vs. $10.4M) but remains unprofitable with negative ROE and net margin; market cap is about $2.9B and the 12‑month range is $7.99–$109.00.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $140.6250.

Several research analysts have recently commented on the company. HC Wainwright lifted their price objective on Nektar Therapeutics from $165.00 to $185.00 and gave the stock a "buy" rating in a report on Monday, April 20th. Oppenheimer reiterated an "outperform" rating and issued a $140.00 price objective on shares of Nektar Therapeutics in a report on Friday, March 13th. Wall Street Zen upgraded Nektar Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, April 11th. William Blair upgraded Nektar Therapeutics from a "market perform" rating to an "outperform" rating in a report on Tuesday, February 10th. Finally, Piper Sandler restated an "overweight" rating and set a $105.00 price target on shares of Nektar Therapeutics in a report on Monday, January 26th.

More Nektar Therapeutics News

Here are the key news stories impacting Nektar Therapeutics this week:

• Neutral Sentiment: Multiple investor‑rights firms are actively notifying shareholders of a May 5, 2026 lead‑plaintiff deadline and soliciting clients to participate in a securities class action regarding alleged disclosures during the Feb–Dec 2025 period. These are procedural notices that increase attention and potential plaintiff coordination. NKTR DEADLINE: ROSEN (Apr 30)
• Negative Sentiment: Pomerantz LLP has filed a federal class action against Nektar and certain officers (filed in N.D. Cal.), alleging violations of the federal securities laws for purchases between Feb. 26, 2025 and Dec. 15, 2025 — this formal filing escalates litigation risk and could lead to discovery, legal costs or settlement exposure. Pomerantz Filing (Apr 30)
• Negative Sentiment: Additional class actions/claims were publicized by Glancy Prongay Wolke & Rotter, Bronstein Gewirtz & Grossman, Schall, Faruqi and others seeking lead plaintiff roles and damages for the same class period; overlapping suits increase the chance of consolidated litigation and higher defense/settlement costs. Glancy Prongay (May 1)
• Negative Sentiment: At least one notice (SueWallSt summary) highlights substantive allegations that the pivotal REZOLVE‑AA trial included four patients who should not have been randomized, which analysts say may have affected the trial’s primary endpoint. Allegations about trial‑data integrity are the most material — they can influence regulator/investor confidence and raise potential for larger damages if proven. SueWallSt Alert (Apr 30)
• Negative Sentiment: Investor takeaway: the legal wave raises downside risk (defense costs, distraction, possible settlements or adverse findings). That risk can weigh on valuation until the company resolves suits or provides clarifying disclosures; however, short‑term share moves can still be driven by clinical updates, broader biotech market sentiment, or technical factors. Bronstein Notice (May 1)

Nektar Therapeutics Stock Performance

NKTR opened at $86.46 on Monday. The company has a market cap of $2.92 billion, a P/E ratio of -8.48 and a beta of 1.24. The business's 50-day moving average price is $76.64 and its 200-day moving average price is $60.38. Nektar Therapeutics has a 12 month low of $7.99 and a 12 month high of $109.00.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($1.78) EPS for the quarter, topping the consensus estimate of ($2.69) by $0.91. The firm had revenue of $21.81 million for the quarter, compared to the consensus estimate of $10.44 million. Nektar Therapeutics had a negative return on equity of 380.32% and a negative net margin of 297.07%. Equities research analysts forecast that Nektar Therapeutics will post -10.02 earnings per share for the current fiscal year.

Insider Transactions at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 423 shares of the business's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total transaction of $30,879.00. Following the transaction, the chief executive officer owned 75,489 shares in the company, valued at $5,510,697. The trade was a 0.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its holdings in Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 210 shares during the period. Deutsche Bank AG boosted its position in Nektar Therapeutics by 0.8% during the 4th quarter. Deutsche Bank AG now owns 90,743 shares of the biopharmaceutical company's stock valued at $3,837,000 after acquiring an additional 743 shares in the last quarter. Bayforest Capital Ltd boosted its position in Nektar Therapeutics by 51.3% during the 4th quarter. Bayforest Capital Ltd now owns 2,541 shares of the biopharmaceutical company's stock valued at $107,000 after acquiring an additional 862 shares in the last quarter. FNY Investment Advisers LLC boosted its position in Nektar Therapeutics by 70.6% during the 3rd quarter. FNY Investment Advisers LLC now owns 2,602 shares of the biopharmaceutical company's stock valued at $148,000 after acquiring an additional 1,077 shares in the last quarter. Finally, XTX Topco Ltd boosted its position in Nektar Therapeutics by 22.0% during the 4th quarter. XTX Topco Ltd now owns 7,196 shares of the biopharmaceutical company's stock valued at $304,000 after acquiring an additional 1,299 shares in the last quarter. Hedge funds and other institutional investors own 75.88% of the company's stock.

About Nektar Therapeutics

Nektar Therapeutics NASDAQ: NKTR is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body's immune system to treat cancer and other serious diseases.

Nektar's product portfolio and pipeline include a range of clinical-stage and partnered programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.